In pediatrics as well, the first encouraging data are beginning to emerge: Dolinger et al. described positive outcomes with 75% steroid-free remission at 6 months in 16 young IBD patients treated with several combinations of DTT (not including an anti-TNFα) [96]. This evidence concerns the gene TNF and inflammatory bowel disease.